baber/WOPTO huggingface dataset:
Patent NZ-554899-A (NZ)
Title: Methods for extending the life of alloy steel welded joints by elimination and reduction of the haz
Inventor: COLEMAN KENT K
IPC: B23K9/067
Filed: 2005-09-19
Abstract: A method for welding together two alloy steel pieces 202, 204 comprises buttering the surface of the first alloy steel metal piece 202 with a nickel-based filler metal at a thickness sufficient to isolate a heat-affected zone in the first alloy steel metal piece 202 from subsequent welding to produce a first buttered surface, heat-treating the heat-affected zone in the first alloy steel metal piece to produce a heat-treated first buttered surface 206, buttering the surface of the second alloy steel metal piece 204 with the nickel-based filler metal at a thickness sufficient to isolate a heat-affected zone in the second alloy steel metal piece 204 from subsequent welding to produce a second buttered surface, and heat-treating the heat-affected zone in the second alloy steel metal piece 204 to produce a heat-treated second buttered surface 208, and welding the heat-treated first buttered surface to the heat-treated second buttered surface with the nickel-based filler metal 210.
Patent NZ-565338-A (NZ)
Title: Rodeo or riding device incorporating arms, pivots and a driving means for moving a rider support in an elliptical motion
Inventor: CHUANG JIN CHEN
IPC: A63G19/20
Filed: 2008-01-23
Abstract: A riding device is disclosed. The riding device comprises a column (11) extending from a base (10) and an arm (60) pivotally coupled to the column with a pivot pin (17). The device further comprises a carrier (30) supported on the base (10) and movable relative to the base. The carrier (30) is pivotally coupled to the arm (60) with a link (16) and pivot pole (18) which is spaced from the pivot pin (17) for allowing the pivot pole (18) and the link (16) to be moved in a curved moving stroke around the pivot pin (17), and up and down relative to the base (10). The arrangement allows a rider support (50) to be moved in concert with the carrier (30)l. The device further comprises means (20) for moving the carrier (30) and rider support (50) in an elliptical and reciprocating action relative to the base (10).
Patent NZ-565794-A (NZ)
Title: Shoe insole
Inventor: CHESKIN MELVYN P
IPC: A43B7/22
Filed: 2006-04-20
Abstract: An insole 20 for cushioning of the foot and control of foot motion includes a base 22, a top cover sheet 36, and a stability cradle 24 made of a semi-rigid material, having openings 60, 62 extending from the top side to the bottom side, and joined to the bottom of the base to form first, second and third recesses in the bottom surface of the insole into which a lateral heel pod 26, a medial heel pod 28, and a lateral midfoot pod 30 can be respectively inserted. The material properties of the pods may be selected to help control foot motion.
Patent NZ-567006-A (NZ)
Title: Hexahydro cyclooctyl pyrazole cannabinoid modulators
Inventor: LIOTTA FINA
IPC: A61K31/416
Filed: 2006-09-22
Abstract: Disclosed is a hexahydro-cyclooctyl pyrazole having a structure according to formula (I) or a salt thereof wherein the dashed lines between positions 2-3 and positions 3a-9a in formula (I) represent locations for each of two double bonds present when X1R1 is present. The dashed lines between positions 3-3a and positions 9a-1 in formula (I) represent locations for each of two double bonds present when X2R2 is present. The dashed line between position 9 and X4R4 in formula (I) represents the location for a double bond. X1 is absent or lower alkylene, X2 is absent or lower alkylene wherein only one of X1R1 and X2R2 are present. X3 - X5, Z1 - Z3 and R1 - R10 are defined in the specification. Also disclosed is the use of the pyrazole in the manufacture of a medicament for treating, ameliorating or preventing a cannabinoid receptor mediated disease e.g. diabetes, mood disorders and cancer.
Patent NZ-572653-A (NZ)
Title: Recombinant Lol p 5, Phl p 5 and Poa p 5 allergens with reduced IgE binding but undiminished T-cell antigenicity
Inventor: DEWEERD NICOLE
IPC: C12N15/09
Filed: 2002-09-13
Abstract: Disclosed is a recombinant pollen allergen variant comprising reduced numbers of IgE epitopes, which variant exhibits reduced binding capacity for IgE and/or which exhibits reduced IgE production stimulatory activity while retaining T-cell antigenicity selected from the list consisting of Lolium perene pollen allergen 5 (Lol p 5) variants carrying the mutations: a. K57A, G273A, K275A, K172N, F173L, T174A and V175A (mut 6); b. K57A, G273A, K275A, A204G, V205A and K206A (mut 7); c. K57A, deltaG272, K172N, F173L, T174A and V175A (mut 8); or d. K57A, deltaG272, A204G, V205A and K206A (mut 9); or a recombinant variant Phleum pratense pollen allergen 5 (Phl p 5) or Poa pratense pollen allergen 5 (Poa p 5) protein allergen corresponding to said recombinant variant of Lol p 5. (62) Divided Out of 531882
Patent NZ-572664-A (NZ)
Title: Composites of inorganic and/or organic microparticles and nano-dolomite particles
Inventor: BURI MATTHIAS
IPC: C09C1/00
Filed: 2007-06-05
Abstract: Disclosed is a composite comprising inorganic and/or organic pigment and/or filler particles coated with a composition comprising dolomite particles and a binder. The spherical equivalent diameter of the pigment and/or filler particles is in the micrometer range and the spherical equivalent diameter of the dolomite particles is in the nanometre range. The binder is a copolymer comprising as monomers one or more dicarboxylic acids and one or more monomers from the group diamines, triamines, dialkanolamines or trialkanolamines. The inorganic particles are preferably selected from talc, mica or mixtures thereof while the organic particles are preferably selected from particles based on polyethylenes, polypropylenes, polyethylene terephthalates or polystyrenes. Also disclosed is the method of making the composite; an aqueous slurry comprising the composite; the use of the composite; and a filler, a filtration aid, a pigment and a coating colour comprising of the composite.
Patent NZ-573791-A (NZ)
Title: Remote manipulator for individually moving and separating multiple sub-conductors in a live or energised single phase bundle
Inventor: DEVINE CLIFFORD WILLIAM
IPC: H02G7/12
Filed: 2006-06-02
Abstract: A remote manipulator for moving and separating multiple sub-conductors in an energized or live single phase bundle. The manipulator includes a rigid support member (44) mountable on the end of a telescopic boom (22,24) and adjustable via a hydraulic ram or cylinder (46). Two actuators (40a) are mounted on the support member, each actuator is independently operated. An insulator (36a,36b) is connected to each actuator via a cable (38a,38b). A selectively releasable coupler or hook (46a,46b) is mounted on each insulator for selectively releasing a corresponding sub-conductor in an energized single phase bundle of sub-conductors. When selectively actuated each actuator is arranged so as to extend corresponding insulators independently of one another from the support member. In this way the insulators are separated from each other by a separation distance. The surge impedance loading of the single phase bundle is improved by increasing the separation distance.
Patent NZ-577089-A (NZ)
Title: A system and method for adjustment of a milking location
Inventor: HALLSTROM ANDERS
IPC: A01K1/12
Filed: 2007-12-21
Abstract: A system and method for the automatic adjustment of at least one interior dimension of a milking location for an animal is disclosed. The milking location comprises an enclosure formed by n confining means, where n is an integer, and n ? 1, where at least one of the confining means is movable. The system comprises a first sensor operable to detect the presence of an animal in the milking location and a control device connected to the first sensor, and operable to, when the presence of an animal in the milking location is detected, move the movable confining means stepwise, in order to adjust the at least one interior dimension of the milking location to the animal. Another sensor is connected to the control device and is operable to detect a position value of at least one part of the confining means. A memory is connected to the control device and is operable to store, in connection with the identity of an animal, the final position value of the movable confining means for the animal when adjustment of the milking location is finished. The control device is operable to move the movable confining means by making use of the final position value stored in the memory means.
Patent NZ-577837-A (NZ)
Title: NUCLEIC ACID MOLECULE CAPABLE OF BINDING TO RABBIT-DERIVED IgG ANTIBODY
Inventor: YOSHIDA YOSHIHITO
IPC: C12N15/09
Filed: 2007-11-22
Abstract: Disclosed is an RNA nucleic acid molecule having an ability to bind a rabbit IgG antibody, which includes an RNA sequence set forth in any of SEQ ID NOs 1 to 5 or an RNA sequence having 90% identity or higher homology to the RNA sequence.
Patent NZ-578238-A (NZ)
Title: Artifical teethridge with an integral fang for the attachment of a prosthesis
Inventor: CHEN LIEH-TANG
IPC: A61C8/00
Filed: 2008-01-28
Abstract: Disclosed is an artificial teethridge with fangs. The teethridge is attachable to an alveolar bone. The artificial teethridge has an arched cross-section with an arched top and an arched bottom. The bottom of the artificial teethridge forms a concave profile to fit with the curved structure of the top of the alveolar bone. The artificial teethridge can be mounted and fixed on the alveolar bone. A plurality of fangs taper from a narrower fang top to a wider fang bottom, each fang bottom being integral with the top of the artificial teethridge. A prosthesis is integral with the top of the fangs. The artificial teethridge, the fangs, and the prosthesis form an integral structure.
Patent NZ-583664-A (NZ)
Title: Co-crystals of pyrimethanil and dithianon
Inventor: VOGEL RALF
IPC: C07D239/42
Filed: 2008-08-22
Abstract: Disclosed are co-crystals of pyrimethanil and dithianon, which, in a X-ray powder diffractogram at 25 degrees C, show at least three of the following reflexes: 2 theta = 7.46 ± 0.20 2 theta = 9.98 ± 0.20 2 theta = 13.28 ± 0.20 2 theta = 23.09 ± 0.20 2 theta = 24.38 ± 0.20 2 theta = 27.01 ± 0.20. Also disclosed are processes for preparing the co-crystals and their use for controlling phytopathogenic fungi.
Patent NZ-591977-A (NZ)
Title: Process for the preparation of benzonorbornenes
Inventor: GRIBKOV DENIS
IPC: C07C211/61
Filed: 2009-09-28
Abstract: Disclosed is a process for the preparation of 9-dichloromethylene-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-ylamine of formula I which process comprises a) reacting cyclopentadiene with CXCl3, wherein X is chloro or bromo, in the presence of a radical initiator to a compound of formula II wherein X is chloro or bromo, or aa) reacting cyclopentadiene with CXCl3, wherein X is chloro, in the presence of a metal catalyst to a compound of formula II wherein X is chloro, b) reacting the compound of formula II with a base in the presence of an appropriate solvent to the compound of formula III, c) and converting the compound of formula III in the presence of 1,2-dehydro-6-nitrobenzene to the compound of formula IV and d) hydrogenating the compound of formula IV with a hydrogen source in the presence of a metal catalyst.
Patent NZ-593854-A (NZ)
Title: Gene expression profiling for the identification, monitoring, and treatment of prostate cancer
Inventor: BANKAITIS-DAVIS DANUTE M
IPC: C12Q1/68
Filed: 2010-01-06
Abstract: Disclosed is a method for evaluating the presence of prostate cancer in a subject, the method comprising: determining a quantitative measure of an amount of secreted protein acidic and cysteine-rich (SPARC) in a sample obtained previously from the subject, wherein said sample comprises RNA; comparing the quantitative measure of SPARC in the sample to a reference value of SPARC; and determining that the subject has prostate cancer when the comparison at (b) indicates a higher quantitative measure of SPARC in the sample than the reference value of SPARC or determining that the subject does not have prostate cancer when the comparison at (b) indicates a lower or equivalent quantitative measure of SPARC in the sample than the reference value of SPARC, wherein an amount of SPARC in the sample positively correlates with an increased likelihood of the subject having prostate cancer.
Patent NZ-594194-A (NZ)
Title: Induction unit for uniting air flows
Inventor: LARSSON PER AKE
IPC: F24F1/01
Filed: 2009-12-23
Abstract: 594194 The invention relates to an induction unit for uniting air flows. The induction unit comprises at least one induction duct (21) in communication with a primary air duct (30) formed in the wall of the induction duct. At least one first opening (28) for a primary air flow (Fl) is connected to the primary air duct which opens into the induction duct. A secondary air intake (22) is arranged at the upstream end of the induction duct for the intake of a secondary air flow (F2) from a space surrounding the induction unit. The inwards primary air flow generates an induction, or Venturi, effect which causes air to be drawn in through the secondary intake and subsequently merge with the air from the primary air flow. The secondary air intake is directed substantially parallel to a center line (A) of the induction duct, which creates a more uniform, less turbulent, air flow. The combined (F3) primary and secondary air flow is returned via an outlet (24) located at the downstream end of the induction unit.
Patent NZ-595832-A (NZ)
Title: A contoured panel with increasing density across its width, convex features having a high density surface
Inventor: LYNCH STEVEN K
IPC: B29C33/38
Filed: 2010-07-21
Abstract: Disclosed is a building panel with varying densities providing more uniform densities when the panel is moulded. The panel comprises a first major surface, a second surface opposite the first surface and a core disposed between the first and second major surfaces. A contoured region is formed in the panel by the application of pressure to the first and second surfaces, where a flow of fibres in the panel and panel density is substantially uniform along the first major surface and decreases through the core of the panel. The contoured region comprises a convex feature, a first adjacent base and a second adjacent base, the apex of the convex feature having a first caliper, the first base having a second caliper smaller than the first caliper, and the second base having a third caliper smaller than the second caliper.
Patent NZ-596091-A (NZ)
Title: Antagonistic human light-specific human monoclonal antibodies
Inventor: GRANGER STEVEN W
IPC: C07K16/28
Filed: 2007-08-24
Abstract: Disclosed is an isolated antibody or a hLIGHT binding fragment thereof, that specifically binds to the native form of soluble hLIGHT but does not bind to the denatured hLIGHT, wherein said antibody or fragment does not bind to soluble hLIGHT boiled in 2xSDS sample buffer.
Patent NZ-598224-A (NZ)
Title: A support base with foldable legs and base aperture for fixing orientation of upright
Inventor: SMYTH ALLEN TRAVERS
IPC: A47G25/12
Filed: 2012-02-14
Abstract: The support base is used for supporting an upstanding item, typically a road sign. It has a sleeve and upper and lower plates, with the sleeve extending through the upper plate and being capable of releasably receiving an end of an item. The lower plate has a non-circular aperture so that the base can fix the item in a particular orientation. The base also has at least three legs which are movable from an extended to a collapsed position. (61) Addition to 563387
Patent NZ-600310-A (NZ)
Title: 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts
Inventor: SOLA-CARANDELL LLUIS
IPC: A61K9/16
Filed: 2010-11-25
Abstract: 600310 The present disclosure relates to 4-[-2-[[5-methyl-1 -(2-naphthalenyl)-1 H-pyrazol-3- yl]oxy]ethyl]morpholine salts, specifically to the hydrochloride, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of sigma receptor associated diseases.
Patent NZ-601498-A (NZ)
Title: Process for the preparation of 2-(cyclohexylmethyl)-n-{ 2-[(2s)-1-methylpyrrolidin-2-yl]ethyl} -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
Inventor: ELENBAAS STEVEN
IPC: A61K31/4725
Filed: 2011-03-04
Abstract: Disclosed is a process for preparing 2-(cyclohexylmethyl)-N-{ 2-[(2S)-1-methylpyrrolidin-2-yl]ethyl} -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide, or a pharmaceutically acceptable salt thereof, or a solvate or hydrate of a pharmaceutically acceptable salt comprising: a) coupling (-)-2-(2-aminoethyl)-1-methylpyrrolidine with an amine-protected tetrahydroquinoline-7-sulfonyl chloride to give an amine-protected N-{ 2-[(2S)-1-methylpyrrolidin-2-yl]ethyl} -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide; b) deprotecting the amine-protected N-{ 2-[(2S)-1-methylpyrrolidin-2-yl]ethyl} -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide to give N-{ 2-[(2S)-1-methylpyrrolidin-2-yl]ethyl} -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide or a salt thereof; c) reductively aminating N-{ 2-[(2S)-1-methylpyrrolidin-2-yl]ethyl} -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide or a salt thereof with cyclohexanecarboxaldehyde to form 2-(cyclohexylmethyl)-N-{ 2-[(2S)-1-methylpyrrolidin-2-yl]ethyl} -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide; d) optionally reacting 2-(cyclohexylmethyl)-N-{ 2-[(2S)-1-methylpyrrolidin-2-yl]ethyl} -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide, or a hydrate or solvate thereof, with a stoichiometric amount or an excess of a salt-forming acid in a solvent to form a salt or a hydrate or solvate thereof; and e) optionally recrystallizing the product of step d). Also disclosed is a process for preparing 2-(2,2,2-trifluoroacetyl)-N-{ 2-[(2S)-1-methylpyrrolidin-2-yl]ethyl} -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide comprising coupling 2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-7-sulfonyl chloride and (-)-2-(2-aminoethyl)-1-methylpyrrolidine in the presence of a base and in an inert solvent.
Patent NZ-604018-A (NZ)
Title: Furanyl compounds and the use thereof
Inventor: SWINDLEHURST CATHY A
IPC: C07D307/68
Filed: 2011-06-07
Abstract: The disclosure relates to substituted furanyl compounds of formula (I), pharmaceutical compositions comprising the compounds, methods of their preparation, and methods of their use, wherein the variables are as defined in the specification. These furanyl compounds modulate eIF4E activity and also the Hedgehog pathway activity and are useful for the treatment, prevention, and/or amelioration of various disorders, including cancer and proliferative disorders. Further, these compounds are used in combination with surgery, radiation therapy, immuno therapy and/or one or more additional anticancer drugs for the treatment, prevention, and/or amelioration of cancer and proliferative disorders.
Patent NZ-618120-A (NZ)
Title: New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Inventor: FISCHER ANDREAS
IPC: A61P25/04
Filed: 2012-09-18
Abstract: Disclosed are pharmaceutical compositions for the treatment of opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. Also disclosed are tablets for sublingual administration comprising (a) microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof in associative admixture with particles comprising citric acid; (b) a pharmacologically-effective amount of naloxone, or a pharmaceutically acceptable salt thereof; and (c) a disintegrant selected from the group croscarmellose sodium, sodium starch glycolate, crosslinked polyvinylpyrrolidone and mixtures thereof. The compositions are intended for use in the treatment of opioid dependency/addiction and/or pain.
Patent NZ-624872-A (NZ)
Title: Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
Inventor: SMITH ALEXANDER BAXTER
IPC: C07D498/04
Filed: 2012-12-20
Abstract: The disclosure relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes. An example of the compounds is { (S)-3-[4-(5-difluoromethyl-6-methoxy-pyridin-3-yl)-5-methyl-3,4-dihydro-2H-benzo[1 ,4]oxazin-6-yloxy]-pyrrolidin-1-yl} -(1,1-dioxo-hexahydro-1Iambda*6*thiopyran-4-yl)-methanone.
Patent NZ-704584-A (NZ)
Title: Liquid stable virus vaccines
Inventor: O’CONNELL KEVIN
IPC: A61K39/295
Filed: 2013-08-16
Abstract: The present invention discloses liquid stable vaccines that comprise a live attenuated virus, 10-30% sugar additive, and an amino acid. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
Patent NZ-718128-A (NZ)
Title: Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
Inventor: LAURITZEN CONNI
IPC: C07D309/14
Filed: 2014-09-08
Abstract: The invention relates to amino acid derivatives of Formula (I) which possess a bi-phenyl core and 1,4-diazinane substituent. These derivatives are claimed as selective dipeptidyl peptidase I inhibitors for the treatment of, among others, asthma, chronic obstructive pulmonary disease, bronchiectasis, cystic fibrosis, and alpha-1 antitrypsin deficiency.
Patent NZ-721622-A (NZ)
Title: Steroid compound for use in the treatment of hepatic encephalopathy
Inventor: DOVERSKOG MAGNUS
IPC: A61P25/00
Filed: 2015-01-14
Abstract: The present invention provides the steroidal compound 3-ethynyl-3-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
Patent NZ-727950-A (NZ)
Title: Mesenchymal stromal cells for treating sepsis
Inventor: DALEMANS WILFRIED
IPC: A61K35/28
Filed: 2015-06-30
Abstract: The invention relates to the use of adipose tissue derived stromal cells (ASCs) for treating sepsis in a subject. The invention provides compositions, uses and methods for the treatment of sepsis.
Patent NZ-746011-A (NZ)
Title: Glycoalkaloid combinations and various uses thereof
Inventor: CHAM BILL ELLIOT
IPC: A61P17/00
Filed: 2017-03-03
Abstract: The present invention relates to the use of glycoalkaloids, such as solasonine and solamargine, in treatment of cancer such as skin cancer, and to compositions for use in such treatment. More particularly the present invention relates to providing an improved, substantially stable formulation for the glycoalkaloids which minimises or reduces degradation of these active molecules.
Patent NZ-748980-A (NZ)
Title: Fire-stopping product
Inventor: OUTRAM IAN
IPC: E04B1/94
Filed: 2017-05-09
Abstract: A fire-stopping material for use in sandwich panels is provided, wherein the fire- stopping material comprises a resilient, porous material at least partially impregnated with an intumescent agent. A panel for an internal wall and an internal wall are also provided, comprising the fire-stopping material disposed between two substantially parallel boards, such as plaster boards. A method of providing a service penetration through an internal wall is also provided. The invention is concerned with reactive technology implemented in dividing interior walls. Wherein cables can be passed through the material without need for a duct or piping, a cut is made and the cable is pushed through, then the outsides of the material is back filled.